Trials / Completed
CompletedNCT01483560
REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
Phase 3 Study of Metformin in Adults With Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 493 (actual)
- Sponsor
- University of Glasgow · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | 3 years treatment duration |
| DRUG | Placebo | 3 years duration |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2017-03-19
- Completion
- 2017-04-18
- First posted
- 2011-12-01
- Last updated
- 2019-06-19
- Results posted
- 2019-06-03
Locations
24 sites across 5 countries: Australia, Canada, Denmark, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT01483560. Inclusion in this directory is not an endorsement.